Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol. 2006;18:430–7.
Article
CAS
PubMed
Google Scholar
Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol. 2006;80:3122–5.
Article
PubMed Central
PubMed
Google Scholar
Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol. 2006;7:173–8.
Article
CAS
PubMed
Google Scholar
Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46–53.
Article
CAS
PubMed
Google Scholar
Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis. 2013;208:1231–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2012;86:277–83.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, et al. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control. Nat Med. 2013;19:930–3.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol. 2007;178:2746–54.
Article
CAS
PubMed
Google Scholar
Chen DY, Balamurugan A, Ng HL, Cumberland WG, Yang OO. Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. Blood. 2012;120:100–11.
Article
PubMed Central
CAS
PubMed
Google Scholar
Borghans JAM, Mølgaard A, de Boer RJ, Keşmir C. HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24. PLoS One. 2007;2:e920.
Article
PubMed Central
PubMed
Google Scholar
Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD. Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses. 2011;27:391–8.
Article
PubMed Central
CAS
PubMed
Google Scholar
Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol. 2007;81:12382–93.
Article
PubMed Central
CAS
PubMed
Google Scholar
Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol. 2007;81:12608–18.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chopera DR, Wright JK, Brockman MA, Brumme ZL. Immune-mediated attenuation of HIV-1. Future Virol. 2011;6:917–28.
Article
PubMed Central
CAS
PubMed
Google Scholar
Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, et al. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol. 2010;84:11937–49.
Article
PubMed Central
CAS
PubMed
Google Scholar
Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5:e1000365.
Article
PubMed Central
PubMed
Google Scholar
Kulkarni V, Rosati M, Valentin A, Ganneru B, Singh AK, Yan J, et al. HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One. 2013;8:e60245.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kulkarni V, Valentin A, Rosati M, Alicea C, Singh AK, Jalah R, et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in Macaques. PLoS One. 2014;9:e86254.
Article
PubMed Central
PubMed
Google Scholar
Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007;3:e157.
Article
PubMed Central
PubMed
Google Scholar
Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, et al. Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol. 2010;84:4461–8.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, et al. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One. 2013;8:e64405.
Article
PubMed Central
CAS
PubMed
Google Scholar
Niu L, Termini JM, Kanagavelu SK, Gupta S, Rolland MM, Kulkarni V, et al. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine. 2011;29:2110–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–93.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20.
Article
CAS
PubMed
Google Scholar
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369:2083–92.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rolland M, Tovanabutra S, de Camp AC, Frahm N, Gilbert PB, Sanders-Buell E, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17:366–71.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mothe B, Llano A, Ibarrondo J, Zamarreño J, Schiaulini M, Miranda C, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One. 2012;7:e29717.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreño J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med. 2011;9:208.
Article
PubMed Central
CAS
PubMed
Google Scholar
Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014;14:291–300.
Article
CAS
PubMed
Google Scholar
Lind A, Brekke K, Sommerfelt M, Holmberg JO, Aass HCD, Baksaas I, et al. Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Vaccine. 2013;31:4611–8.
Article
CAS
PubMed
Google Scholar
Karlsson I, Kløverpris H, Jensen KJ, Stryhn A, Buus S, Karlsson A, et al. Identification of conserved subdominant HIV Type 1 CD8(+) T Cell epitopes restricted within common HLA Supertypes for therapeutic HIV Type 1 vaccines. AIDS Res Hum Retroviruses. 2012;28:1434–43.
Article
CAS
PubMed
Google Scholar
Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007;13:100–6.
Article
CAS
PubMed
Google Scholar
Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16:319–23.
Article
PubMed Central
CAS
PubMed
Google Scholar
Nickle DC, Rolland M, Jensen MA, Pond SLK, Deng W, Seligman M, et al. Coping with viral diversity in HIV vaccine design. PLoS Comput Biol. 2007;3:e75.
Article
PubMed Central
PubMed
Google Scholar
Fischer W, Liao HX, Haynes BF, Letvin NL, Korber B. Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol. 2008;4:e15. author reply e25.
Article
PubMed Central
PubMed
Google Scholar
Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol. 2004;78:2187–200.
Article
PubMed Central
CAS
PubMed
Google Scholar
Nasioulas G, Zolotukhin AS, Tabernero C, Solomin L, Cunningham CP, Pavlakis GN, et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol. 1994;68:2986–93.
PubMed Central
CAS
PubMed
Google Scholar
Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol. 1997;71:4892–903.
PubMed Central
CAS
PubMed
Google Scholar
Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol. 1992;66:150–9.
PubMed Central
CAS
PubMed
Google Scholar
Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, von Gegerfelt A, et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine. 2011;29:6742–54.
Article
PubMed Central
CAS
PubMed
Google Scholar
Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem. 2013;288:6763–76.
Article
PubMed Central
CAS
PubMed
Google Scholar
Létourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007;2:e984.
Article
PubMed Central
PubMed
Google Scholar
Nkolola JP, Wee EG-T, Im E-J, Jewell CP, Chen N, Xu X-N, et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 2004;11:1068–80.
Article
CAS
PubMed
Google Scholar
PeptGen Peptide Generator [http://www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html]
Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A. 2013;110:2975–80.
Article
PubMed Central
CAS
PubMed
Google Scholar
Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 2006;27:11–6.
Article
CAS
PubMed
Google Scholar
Le Gall S, Stamegna P, Walker BD. Portable flanking sequences modulate CTL epitope processing. J Clin Invest. 2007;117:3563–75.
Article
PubMed Central
PubMed
Google Scholar
Yusim K, Korber BT, Brander C, Barouch DH, de Boer RJ, Haynes BF, et al. HIV Molecular Immunology. Los Alamos, New Mex: Los Alamos Natl Lab Theor Biol Biophys; 2011.
Google Scholar
Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009;4:e6687.
Article
PubMed Central
PubMed
Google Scholar
Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608–18.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kuiken C, Foley B, Leitner T, Apetrei C, Hahn BH, Mizrachi I, et al. HIV Sequence Compendium. LA–UR: Theor Biol Biophys Group, Los Alamos Natl Lab NM; 2011. p. 11–11440.
Google Scholar
Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1.
Article
PubMed Central
PubMed
Google Scholar
Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol. 2004;78:4463–77.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhang SC, Martin E, Shimada M, Godfrey SB, Fricke J, Locastro S, et al. Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol. 2012;188:5924–34.
Article
PubMed Central
CAS
PubMed
Google Scholar
Llano A, Williams A, Olvera A, Silvia-Arrieta S, Brander C. Best-Characterized HIV-1 CTL Epitopes: The 2013 Update. Los Alamos, New Mex: HIV Mol Immunol Los Alamos Natl Lab Theor Biol Biophys; 2013. p. 3–25.
Google Scholar
Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, Bhella D, et al. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 2013;9:e1003461.
Article
PubMed Central
CAS
PubMed
Google Scholar
Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535–51.
Article
CAS
PubMed
Google Scholar
O’Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med. 2001;7:379–81.
Article
PubMed
Google Scholar
Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol. 2005;79:8480–92.
Article
PubMed Central
CAS
PubMed
Google Scholar
Dorrell L, Yang H, Ondondo B, Dong T, Gleria K, Suttill A, et al. Expansion and diversification of virus-specific T cells following immunization of Human Immunodeficiency Virus Type 1 ( HIV-1) -infected individuals with a recombinant modified vaccinia virus ankara/HIV-1 gag vaccine. J Virol. 2006;80:4705–16.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol. 2007;88(Pt 1):1–12.
Article
CAS
PubMed
Google Scholar
Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, Wahl A, et al. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol. 2009;182:7763–75.
Article
PubMed Central
CAS
PubMed
Google Scholar
Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine. 2010;28:4827–36.
Article
PubMed Central
CAS
PubMed
Google Scholar
Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Martins MA, Wilson NA, Piaskowski SM, Weisgrau KL, Furlott JR, Bonaldo MC, et al. Vaccination with gag, vif, and nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol. 2014;88:7493–516.
Article
PubMed Central
PubMed
Google Scholar
Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature. 2012;491:129–33.
Article
CAS
PubMed
Google Scholar
Rolland M, Manocheewa S, Swain JV, Lanxon-Cookson EC, Kim M, Westfall DH, et al. HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. J Virol. 2013;87:5461–7.
Article
PubMed Central
CAS
PubMed
Google Scholar
Manocheewa S, Swain JV, Lanxon-Cookson E, Rolland M, Mullins JI. Fitness costs of mutations at the HIV-1 capsid hexamerization interface. PLoS One. 2013;8:e66065.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, et al. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog 2015, in press.
Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis. 2012;206:552–61.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang H-C, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36:491–501.
Article
PubMed Central
CAS
PubMed
Google Scholar
Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517:381–5.
Article
CAS
PubMed
Google Scholar
Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, Linde CH, et al. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol. 2007;179:6638–50.
Article
CAS
PubMed
Google Scholar
Rolland M, Frahm N, Nickle DC, Jojic N, Deng W, Allen TM, et al. Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. PLoS One. 2011;6:e17969.
Article
PubMed Central
CAS
PubMed
Google Scholar
García F, Bernaldo de Quirós JCL, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011;29:8309–16.
Article
PubMed
Google Scholar
Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, Seaman MS, et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol. 2014;88:1249–58.
Article
PubMed Central
PubMed
Google Scholar
Hanke T, McMichael AJ. HIV-1: from escapism to conservatism. Eur J Immunol. 2011;41:3390–3.
Article
CAS
PubMed
Google Scholar
Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine. 2005;23:4292–301.
Article
CAS
PubMed
Google Scholar
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS. 2008;22:1313–22.
Article
CAS
PubMed
Google Scholar
Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis. 2013;207:1829–40.
Article
PubMed Central
CAS
PubMed
Google Scholar
Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010;202:705–16.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hansen SG, Piatak M, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013;502:100–4.
Article
CAS
PubMed
Google Scholar
Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013;340:1237874.
Article
PubMed
Google Scholar
Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523–7.
Article
PubMed Central
CAS
PubMed
Google Scholar
Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, et al. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS. 2013;27:2841–51.
Article
PubMed
Google Scholar